| Gene symbol | GPC3 | Synonyms | DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB, SGBS, SGBS1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq26.2 | dbXrefs | |
| Description | glypican 3 | ||||
| GTO ID | GTC0525 |
| Trial ID | NCT04405778 |
| Disease | Solid Tumor |
| Altered gene | GPC3 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | TAK-102 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors |
| Year | 2020 |
| Country | Japan |
| Company sponsor | Takeda |
| Other ID(s) | TAK-102-1501|U1111-1247-6429|jRCT1080225204 |
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||